
|Videos|June 22, 2017
Nivolumab With or Without Ipilimumab in Gastroesophageal Junction Cancer
Author(s)Yelena Y. Janjigian, MD
Yelena Y. Janjigian, MD, attending physician, Memorial Sloan Kettering Cancer Center, discusses findings of CheckMate-032, a study of nivolumab (Opdivo) with or without ipilimumab (Yervoy) in patients with advanced/metastatic chemotherapy-refractory gastric, esophageal, or gastroesophageal junction cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
June 2026 in Oncology: A Look Back at FDA Approvals and Decisions
2
New Considerations Arise in Sequencing After Second Relapse in Multiple Myeloma
3
Orca-T Gains FDA Approval in Matched Donor Transplants
4
SC Amivantamab Plus Lazertinib Builds on Evolving Frontline Paradigm in EGFR+ NSCLC
5







































